Single-agent IGF-1R mAbs are no longer being explored as an experimental treatment option for ES patients and the most recent Children’s Oncology Group’s study, AEWS1221, was terminated in March 2019 after ganitumab (Amgen’s IGF-1R-targeted Ab; AMG479) failed to synergize with standard-of-care cytotoxic chemotherapy in newly diagnosed metastatic ES patients. The gene discussed is IGF1R; the disease is Ewing sarcoma.